Ruth Wilson has said she quit "The Affair" because "things didn't feel right" and she "didn't feel safe."
Ruth Wilson has said she quit "The Affair" because "things didn't feel right" and she "didn't feel safe."
The "Asphalt Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
TORONTO (AP) _ Bank Of Montreal (BMO) on Tuesday reported fiscal fourth-quarter earnings of $1.19 billion. The bank, based in Toronto, said it had earnings of $1.78 per share. Earnings, adjusted for amortization costs and costs related to mergers and acquisitions, came to $1.81 per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.48 per share. The bank posted revenue of $5.7 billion in the period. Its revenue net of interest expense was $4.49 billion, also topping Street forecasts. For the year, the company reported profit of $3.79 billion, or $5.61 per share. Revenue was reported as $18.73 billion. Bank of Montreal shares have fallen 6% since the beginning of the year. The stock has dropped 5.5% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMO at https://www.zacks.com/ap/BMO The Associated Press
Keira Bell brought legal action against the Tavistock and Portman NHS Trust.
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION(a) Full name of discloser:Investec Wealth & Investment (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Urban&Civic Plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure30th November 2020 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” 2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)Class of relevant security: InterestsShort positions Number%Number% (1) Relevant securities owned and/or controlled:12,819,7448.83% (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL:12,819,7448.83% All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).(b) Rights to subscribe for new securities (including directors’ and other employee options)Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSUREWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and salesClass of relevant securityPurchase/sale Number of securitiesPrice per unit Ordinary Shares Sale 1,500 343.01p (b) Cash-settled derivative transactionsClass of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c) Stock-settled derivative transactions (including options)(i) Writing, selling, purchasing or varyingClass of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) ExerciseClass of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities)Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable) 4. OTHER INFORMATION(a) Indemnity and other dealing arrangementsDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” N/A (b) Agreements, arrangements or understandings relating to options or derivativesDetails of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” N/A (c) AttachmentsIs a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure:1st December 2020 Contact name:Phil Beardwell Chartered FCSI Telephone number:020 7597 1356 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at firstname.lastname@example.org. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
JD Sports has pulled out of talks with Debenhams after Arcadia called in administrators.
Church & Dwight Co., Inc. (NYSE: CHD) has completed the acquisition of Matrixx Initiatives, Inc., the owner of the ZICAM™ brand for $530 million. The acquisition was structured as a stock purchase that the Company financed with a combination of cash and debt. Zicam is the 1 zinc supplement in the United States in the VMS (vitamins, minerals, and supplements) cough/cold shortening category. Zicam shortens the duration of a cold using zinc as the core active ingredient.
The euro was close to a three-month high on Tuesday as the U.S. dollar fell on expectations of more monetary stimulus from the United States and a strengthening recovery elsewhere pushed up riskier currencies. One of the currencies to watch was the New Zealand dollar, which was on course to reach its highest since June 2018. Investors are short dollars as optimism about promising vaccine trials drives buying of riskier currencies and higher- yielding assets outside the United States.
Palantir must 'ensure the technology they are providing in no way contributes to abuses in the UK’, government told
From Coolie No. 1 to Durgamati, December offers a plethora of programmes for audiences over multiple platforms including Netflix, Amazon Prime Video India, Hotstar Disney+, and Apple TV+
The streaming giant reveals what its 320 million global listeners have been playing this year.
Hakim Ziyech is taking inspiration from Eden Hazard in his bid to become Chelsea’s new talisman. The Morocco winger has made an outstanding start at Stamford Bridge, prompting early comparisons with Hazard, who left a massive void when moving to Real Madrid last year. Ziyech has a long way to go to come close to emulating the Belgian’s influence and even Frank Lampard admitted last week that he’s reluctant to place too much pressure on the 27-year-old by asking him to fill such sizeable shoes.
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Surgical Sealant/Tissue Patch: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report will focus on both biological sealants and synthetic sealants. These sealants can be used in cardiovascular, central nervous system, orthopedic, cosmetic, pulmonary, ophthalmic, and general surgeries. The report will portray the trends and dynamics affecting the market. The report also covers market projections for 2025 and company profiles. By geography, the market has been segregated into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The North America region includes the U.S., Canada, and Mexico; Europe includes Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data have been provided for 2019 as the base year, for 2020, and forecast for 2025.The Report Includes: * An overview of the global surgical sealant/tissue patch market * Estimation of the market size and analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025 * Analysis of current and future market dynamics of surgical sealant/tissue patch market and identification of key drivers, restraints, and opportunities * Description of biological sealants and synthetic sealants and evaluation of current market trends, market size, and market forecast * Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies * Profile description of major market players including, AMS Group, Baxter International, B. Braun, Cardinal Health, Johnson & Johnson, and Stryker Corp.Surgical sealants/tissue patches are a growing market globally, with lots of potential stemming from the advancement of the technology. The growth potential of the market in the forecast period is very promising; as well, growth in the number of surgical procedures will also boost this market.Key Topics Covered: Chapter 1 Introduction * Study Goals and Objectives * Reasons for Doing This Study * Scope of Report * Information Sources * Methodology * Geographic Breakdown * Analyst's Credentials * Custom Research * Related Research ReportsChapter 2 Summary and Highlights * HighlightsChapter 3 Market Dynamics and Technology Background * Overview: Surgical Sealants/Tissue Patches * Market Dynamics * Market Drivers * Market RestraintsChapter 4 Market Breakdown by Type of Material * Global Market for Surgical Sealants/Tissue Patches by Type of Material * Biological Surgical Sealants/Tissue Patches * Synthetic Surgical Sealants/Tissue Patches * Other Surgical Sealants/Tissue PatchesChapter 5 Market Breakdown by Surgical Application * Global Market for Synthetic Surgical Sealants/Tissue Patches by Surgical Application * Cardiovascular * Central Nervous System * Orthopedic * Cosmetic * Pulmonary * Ophthalmic * General Surgery * OthersChapter 6 Market Breakdown by Region * Global Market for Surgical Sealants/Tissue Patches by Region * North America * Europe * Asia-Pacific * South America * Middle East and AfricaChapter 7 Regulatory EnvironmentChapter 8 Competitive Landscape * Global Manufacturer Market Share Analysis * Mergers and Acquisitions, Agreements, Collaborations, and PartnershipsChapter 9 Company Profiles * Advanced Medical Solutions Group Plc * Baxter International Inc. * Becton, Dickinson, and Co. * B. Braun Melsungen Ag * Cardinal Health, Inc. * Cryolife Inc. * Csl Ltd. * Integra Lifesciences Holdings Corp. * Johnson & Johnson (Ethicon Inc.) * Stryker Corp.For more information about this report visit https://www.researchandmarkets.com/r/zhfnbgResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Autumn Nations Cup sees England, France, Ireland, Italy, Scotland and Wales joined by Georgia and Fiji
Rahul Vaidya's mother talks about Disha Parmar and Rahul's relationship.
Follow here for the latest updates on UK politics
French skipper rescued after yacht breaks in half during round-the-world race
Marijuana stocks got a much-needed boost from the results of the recent U.S. election. With the Biden administration set to take office amid key legalization victories in a handful of states, America could become a land of plenty for the cannabis industry -- but the majority of marijuana cultivators are far from being safe bets. Aphria (NASDAQ: APHA) has the distinction of being the only publicly traded and licensed cannabis company to have a positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for the entirety of the 2020 fiscal year.
ENGIE EPS (Paris:EPS) is pleased to announce that on the heels of over 600MWh of secured contracts in the US territories, it has now been awarded a supply contract in Massachusetts.
Laryngoscope Market Research Report by Type (Direct Laryngoscope and Indirect Laryngoscope), by Product (Fiber-optic laryngoscopes, Standard laryngoscopes, and Video laryngoscopes), by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Laryngoscope Market Research Report by Type, by Product, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993434/?utm_source=GNW The Global Laryngoscope Market is expected to grow from USD 126.41 Million in 2019 to USD 207.22 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.58%. Market Segmentation & Coverage: This research report categorizes the Laryngoscope to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Type, the Laryngoscope Market studied across Direct Laryngoscope and Indirect Laryngoscope. Based on Product, the Laryngoscope Market studied across Fiber-optic laryngoscopes, Standard laryngoscopes, and Video laryngoscopes. Based on End-user, the Laryngoscope Market studied across .Clinics, Hospitals, and Medical examination center. Based on Geography, the Laryngoscope Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Laryngoscope Market including Ambu A/S, Entermed, HEINE OPTOTECHNIK GmbH and Co. KG, HERSILL, Hillrom, Inc., Kangji Medical, Medtronic PLC, Olympus Corp, Penlon, Richard Wolf GmbH, Schoelly Fiberoptic GmbH, Teleflex Inc., Timesco Healthcare Ltd, Timesco Healthcare Ltd, Verathon Inc., Vyaire Medical Inc., Welch Allyn, Inc, Welch Allyn, Inc, XION GmbH, and Zhejiang Tiansong Medical Instrument. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Laryngoscope Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market. The report provides insights on the following pointers: 1\. Market Penetration: Provides comprehensive information on the market offered by the key players 2\. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3\. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4\. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5\. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments The report answers questions such as: 1\. What is the market size and forecast of the Global Laryngoscope Market? 2\. What are the inhibiting factors and impact of COVID-19 shaping the Global Laryngoscope Market during the forecast period? 3\. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Laryngoscope Market? 4\. What is the competitive strategic window for opportunities in the Global Laryngoscope Market? 5\. What are the technology trends and regulatory frameworks in the Global Laryngoscope Market? 6\. What are the modes and strategic moves considered suitable for entering the Global Laryngoscope Market? Read the full report: https://www.reportlinker.com/p05993434/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Tate &Lyle today revealed it has bought stevia-producer Sweet Green Fields in the latest move towards zero-calorie, aspartame-free natural sugar substitutes. Its household name brands still seen on supermarket shelves, including Lyle's Golden Syrup and Tate & Lyle, are licensed to America Sugar Refining. On Tuesday the company announced the acquisition of Sweet Green Fields, which is expecting revenues of around $50million in the year to December 31, saying that the move would bring "a fully integrated stevia supply chain to Tate & Lyle".